

Monoclonal Anti-Zika Virus Envelope (E) Protein, Clone ZV-2 (produced *in vitro*)

Catalog No. NR-50414

For research use only. Not for use in humans.

Contributor:

Michael S. Diamond, M.D., Ph.D., Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA

Manufacturer:

BEI Resources

Product Description:

Antibody Class: IgG2c

Mouse monoclonal antibody prepared against the envelope (E) glycoprotein of Zika virus (ZIKV) was purified from clone ZV-2 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of P3X63Ag8.653 mouse myeloma cells with immunized mouse splenocytes. The ZV-2 antibody is non-neutralizing, recognizes an epitope within the ABDE sheet of the DIII domain of the E glycoprotein, and does not cross-react with dengue, Japanese encephalitis, or West Nile viruses.^{1,2,3}

Material Provided:

Each vial of NR-50414 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg/mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-50414 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-50414 specifically recognizes ZIKV-infected cells in indirect immunofluorescence assays. The clone ZV-2 antibody is also reported to function in ELISA and in western blot assays performed under non-reducing conditions.³

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Zika Virus Envelope (E) Protein, Clone ZV-2 (produced *in vitro*), NR-50414.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

NR-50414 is claimed in U.S. Provisional Patent Application number 62/366,782 and the continuations, continuations-in-part, re-issues, and foreign counterparts thereof. For-profit entities wishing to obtain this material must confirm in writing to BEI Resources that they have executed a licensing agreement with the Contributor’s institution. Please contact the Office of Technology Management of the Washington University in St. Louis directly at mta@dom.wustl.edu.

References:

1. Miner, J. J., et al. “Zika Virus Infection During Pregnancy in Mice Causes Placental Damage and Fetal Demise.” *Cell* 165 (2016): 1081-1091. PubMed: 27180225.
2. Zhao, H., et al. “Structural Basis of Zika Virus-Specific Antibody Protection.” *Cell* 166 (2016): 1016-1027. PubMed: 27475895.
3. Diamond, M. S., Personal Communication.

ATCC® is a trademark of the American Type Culture Collection.

